GYRE Gyre Therapeutics Inc
Price (delayed)
$7.09
Market cap
$663.71M
P/E Ratio
50.64
Dividend/share
N/A
EPS
$0.14
Enterprise value
$653.5M
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic
Highlights
The net income has soared by 114% from the previous quarter and by 113% YoY
GYRE's EPS has surged by 110% since the previous quarter and by 110% year-on-year
GYRE's quick ratio is down by 17% since the previous quarter but it is up by 4% year-on-year
GYRE's revenue is down by 7% year-on-year
GYRE's gross profit is down by 6% year-on-year
Key stats
What are the main financial stats of GYRE
Market
Valuations
Earnings
Shares outstanding
93.61M
Market cap
$663.71M
Enterprise value
$653.5M
Price to earnings (P/E)
50.64
Price to book (P/B)
10.47
Price to sales (P/S)
5.7
EV/EBIT
37.55
EV/EBITDA
33.3
EV/Sales
6.18
Revenue
$105.76M
Gross profit
$101.87M
Operating income
$16.16M
Net income
$12.09M
EBIT
$17.41M
EBITDA
$19.63M
Free cash flow
-$5.56M
Per share
Balance sheet
Liquidity
EPS
$0.14
EPS diluted
$0.05
Free cash flow per share
-$0.07
Book value per share
$0.68
Revenue per share
$1.24
TBVPS
$1.45
Total assets
$125.41M
Total liabilities
$27M
Debt
$1.6M
Equity
$63.32M
Working capital
$45.27M
Debt to equity
0.03
Current ratio
3.32
Quick ratio
2.86
Net debt/EBITDA
-0.52
Margins
Efficiency
Dividend
EBITDA margin
18.6%
Gross margin
96.3%
Net margin
11.4%
Operating margin
15.3%
Return on assets
9.8%
Return on equity
19.9%
Return on invested capital
19.9%
Return on capital employed
16.4%
Return on sales
16.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GYRE stock price
How has the Gyre Therapeutics stock price performed over time
Intraday
10.61%
1 week
-19.34%
1 month
-38.88%
1 year
-58.27%
YTD
-41.4%
QTD
-8.16%
Financial performance
How have Gyre Therapeutics's revenue and profit performed over time
Revenue
$105.76M
Gross profit
$101.87M
Operating income
$16.16M
Net income
$12.09M
Gross margin
96.3%
Net margin
11.4%
The company's operating margin has surged by 126% YoY and by 121% QoQ
GYRE's operating income has surged by 124% year-on-year and by 121% since the previous quarter
Gyre Therapeutics's net margin has surged by 114% YoY and by 113% QoQ
The net income has soared by 114% from the previous quarter and by 113% YoY
Growth
What is Gyre Therapeutics's growth rate over time
Valuation
What is Gyre Therapeutics stock price valuation
P/E
50.64
P/B
10.47
P/S
5.7
EV/EBIT
37.55
EV/EBITDA
33.3
EV/Sales
6.18
GYRE's EPS has surged by 110% since the previous quarter and by 110% year-on-year
GYRE's P/B is 55% above its 5-year quarterly average of 6.1 but 52% below its last 4 quarters average of 19.9
The stock's price to sales (P/S) is 50% less than its last 4 quarters average of 10.4 and 43% less than its 5-year quarterly average of 9.1
GYRE's revenue is down by 7% year-on-year
Efficiency
How efficient is Gyre Therapeutics business performance
GYRE's return on sales has surged by 122% year-on-year and by 121% since the previous quarter
GYRE's ROIC has soared by 119% from the previous quarter and by 104% YoY
Gyre Therapeutics's ROA has soared by 113% from the previous quarter and by 104% YoY
The ROE has soared by 109% since the previous quarter
Dividends
What is GYRE's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Gyre Therapeutics financials performed over time
The company's total liabilities fell by 29% YoY
GYRE's quick ratio is down by 17% since the previous quarter but it is up by 4% year-on-year
Gyre Therapeutics's debt is 97% lower than its equity
Gyre Therapeutics's debt to equity has surged by 200% YoY
Gyre Therapeutics's debt has decreased by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.